Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Advisory Committee To Review Human Genome Sciences' Anthrax Treatment

This article was originally published in The Pink Sheet Daily

Executive Summary

The U.S. government already has a stockpile of Human Genome Sciences' ABthrax (raxibacumab) for emergency use.
Advertisement

Related Content

Uncle Sam's Orders: Emergent Scores $107 Mil. For Anthrax Plant, While Bavarian Nordic Delivers On Smallpox
Uncle Sam's Orders: Emergent Scores $107 Mil. For Anthrax Plant, While Bavarian Nordic Delivers On Smallpox
FDA Panel Finds Animal Models Predict Human Response To HGS Anthrax Drug
FDA Panel Finds Animal Models Predict Human Response To HGS Anthrax Drug

Topics

Advertisement
UsernamePublicRestriction

Register

PS070042

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel